Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 77 entries
View as:

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT02873208 Org: User:
Start: 08/07/16 End: 10/17/19 Due: 10/17/20

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03187769 Org: User:
Start: 06/08/17 End: 01/03/22 Due: 01/03/23

A Water Consumption Study of ALKS 5461 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02521857 Org: User:
Start: 07/31/15 End: 09/30/15 Due: 09/30/16

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT02634320 Org: User:
Start: 12/31/15 End: 07/11/17 Due: 07/11/18

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Phase: N/A Priority: Normal
NCT ID: NCT01218997 Org: User:
Start: 08/31/03 End: 03/31/05 Due: 03/31/06

Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03668314 Org: User:
Start: 10/10/18 End: 04/15/19 Due: 04/15/20

A 28 Day Parallel Group Study to Assess the Effects of RDN-929

Phase: N/A Priority: Normal
NCT ID: NCT03963973 Org: User:
Start: 05/16/19 End: 01/22/20 Due: 01/22/21

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT02508506 Org: User:
Start: 07/31/15 End: 12/31/15 Due: 12/31/16

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Phase: N/A Priority: Normal
NCT ID: NCT00801684 Org: User:
Start: 02/28/09 End: 07/31/09 Due: 07/31/10

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

Phase: N/A Priority: Normal
NCT ID: NCT01381107 Org: User:
Start: 05/31/11 End: 07/31/11 Due: 07/31/12

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

Phase: N/A Priority: Normal
NCT ID: NCT03919994 Org: User:
Start: 03/28/19 End: 01/04/23 Due: 01/04/24

ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder

Phase: N/A Priority: Normal
NCT ID: NCT01098435 Org: User:
Start: 05/31/10 End: 06/30/11 Due: 06/30/12

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

Phase: N/A Priority: Normal
NCT ID: NCT02158533 Org: User:
Start: 05/31/14 End: 12/31/15 Due: 12/31/16

A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

Phase: N/A Priority: Normal
NCT ID: NCT02413281 Org: User:
Start: 03/31/15 End: 09/30/15 Due: 09/30/16

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT02320032 Org: User:
Start: 12/31/14 End: 04/30/16 Due: 04/30/17

ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)

Phase: N/A Priority: Normal
NCT ID: NCT01218971 Org: User:
Start: 08/31/02 End: 09/30/04 Due: 09/30/05

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Phase: N/A Priority: Normal
NCT ID: NCT00834080 Org: User:
Start: 03/31/09 End: 05/31/12 Due: 05/31/13

A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02272764 Org: User:
Start: 10/31/14 End: 11/30/14 Due: 11/30/15

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

Phase: N/A Priority: Normal
NCT ID: NCT02218021 Org: User:
Start: 08/31/14 End: 11/30/14 Due: 11/30/15

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Phase: N/A Priority: Normal
NCT ID: NCT01418092 Org: User:
Start: 09/30/11 End: 06/30/12 Due: 06/30/13

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

Phase: N/A Priority: Normal
NCT ID: NCT02158546 Org: User:
Start: 05/31/14 End: 12/31/15 Due: 12/31/16

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Phase: N/A Priority: Normal
NCT ID: NCT03201757 Org: User:
Start: 06/15/17 End: 09/06/23 Due: 09/06/24

Study to Evaluate the Efficacy, Safety and Tolerability of N1539

Phase: N/A Priority: Normal
NCT ID: NCT01084161 Org: User:
Start: 03/31/10 End: 01/31/11 Due: 01/31/12

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02479308 Org: User:
Start: 06/30/15 End: 10/31/15 Due: 10/31/16

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

Phase: N/A Priority: Normal
NCT ID: NCT00156936 Org: User:
Start: 08/31/04 End: 01/31/07 Due: 01/31/08